Novel molecular signatures and potential therapeutics in renal cell carcinomas: insights from a comparative analysis of subtypes

dc.authoridAhmet Cenk Andaç / 0000-0002-4545-3500en_US
dc.authoridAyşegül Çalışkan İşcan / 0000-0003-1887-9167
dc.authorscopusidAhmet Cenk Andaç / 20336962400
dc.authorscopusidAyşegül Çalışkan / 57217079641
dc.authorwosidAhmet Cenk Andaç / AAW-5539-2020
dc.authorwosidAyşegül Çalışkan / GNJ-6483-2022
dc.contributor.authorÇalışkan İşcan, Ayşegül
dc.contributor.authorAndaç, Ahmet Cenk
dc.contributor.authorArga, Kazım Yalçın
dc.date.accessioned2020-08-30T20:06:06Z
dc.date.available2020-08-30T20:06:06Z
dc.date.issued2020
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Ana Bilim Dalıen_US
dc.description.abstractRenal cell carcinomas (RCCs) are among the highest causes of cancer mortality. Although transcriptome profiling studies in the last decade have made significant molecular findings on RCCs, effective diagnosis and treatment strategies have yet to be achieved due to lack of adequate screening and comparative profiling of RCC subtypes. In this study, a comparative analysis was performed on RNA-seq based transcriptome data from each RCC subtype, namely clear cell RCC (KIRC), papillary RCC (KIRP) and kidney chromophobe (KICH), and mutual or subtype-specific reporter biomolecules were identified at RNA, protein, and metabolite levels by the integration of expression profiles with genome-scale biomolecular networks. This approach revealed already-known biomarkers in RCCs as well as novel biomarker candidates and potential therapeutic targets. Our findings also pointed out the incorporation of the molecular mechanisms of KIRC and KIRP, whereas KICH was shown to have distinct molecular signatures. Furthermore, considering the Dipeptidyl Peptidase 4 (DPP4) receptor as a potential therapeutic target specific to KICH, several drug candidates such as ZINC6745464 were identified through virtual screening of ZINC molecules. In this study, we reported valuable data for further experimental and clinical efforts, since the proposed molecules have significant potential for screening and therapeutic purposes in RCCs.en_US
dc.identifier.citationCaliskan, A., Andac, A. C., & Arga, K. Y. (2020). Novel molecular signatures and potential therapeutics in renal cell carcinomas: Insights from a comparative analysis of subtypes. GENOMICS, 112(5), 3166–3178. https://doi.org/10.1016/j.ygeno.2020.06.003en_US
dc.identifier.doi10.1016/j.ygeno.2020.06.003en_US
dc.identifier.endpage3178en_US
dc.identifier.issn0888-7543en_US
dc.identifier.issn1089-8646en_US
dc.identifier.issue5en_US
dc.identifier.pmid32512143en_US
dc.identifier.scopus2-s2.0-85086105791en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage3166en_US
dc.identifier.urihttps://doi.org/10.1016/j.ygeno.2020.06.003
dc.identifier.urihttps://hdl.handle.net/20.500.12713/361
dc.identifier.volume112en_US
dc.identifier.wosWOS:000547954200006en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÇalışkan İşcan, Ayşegülen_US
dc.institutionauthorAndaç, Ahmet Cenken_US
dc.language.isoenen_US
dc.publisherAcademic Press Inc Elsevier Scienceen_US
dc.relation.ispartofGenomicsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiomarkeren_US
dc.subjectDrug Repositioningen_US
dc.subjectKidneyen_US
dc.subjectRenal Cancersen_US
dc.subjectTranscriptomeen_US
dc.subjectSystems Biologyen_US
dc.titleNovel molecular signatures and potential therapeutics in renal cell carcinomas: insights from a comparative analysis of subtypesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
215.pdf
Boyut:
2.34 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text